In my PhD studies at the Department of Endocrinology, Rigshospitalet, I contributed to findings of how age, genetics, heritability, foetal development, obesity and diet/lifestyle influence the epigenome and transcriptome in human blood and tissues with an overall focus on the development of type 2 diabetes. The last year, I have broadened my expertise to also include epigenetics and genetics of haematological cancers, as a researcher at the Department of Haematology, Rigshospitalet. 

I am interested in how epigenetic changes are interacting with the genome and lifestyle exposures in the progression of complex, age-related diseases. In my research, I take advantage of my combined skills in epigenetics and metabolism to explore the role of both in haematological cancer. 

I am currently involved in several projects including 1) the generation of knockout mice (CRISPR/Cas9 editing) for a gene that we believe is important for haematopoiesis and cancer development; 2) the influence of TET2 mutations on epigenetics in blood cells; and 3) the influence of vitamin C supplementation on epigenetic treatment in patients with myelodysplastic syndrome.